SCHEMBL4458688

SCHEMBL4458688

COC1=Cc2ccccc2N(C(=O)Cl)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 9/20 0.43
GPR84 Q9NQS5 1/20 0.41
PTPN1 P18031 1/20 0.38
CES1 P23141 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
SCN4A P35499 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
P2RX1 P51575 2/20 0.36
P2RX3 P56373 2/20 0.36
P2RX7 Q99572 2/20 0.36
IDO1 P14902 1/20 0.35
CDC25A P30304 1/20 0.35
CDC25B P30305 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSP90AA1 P07900 1/20 0.34
PTBP1 P26599 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572434 0.85 P2RX4 (0.62) P2RX4GPR84PTPN1CES1LMNA
SCHEMBL1572458 0.85 LMNA (0.54) P2RX4GPR84PTPN1CES1LMNA
SCHEMBL11115519 0.83 P2RX4 (0.47) P2RX4GPR84PTPN1CES1LMNA
SCHEMBL11118498 0.83 BCHE (0.47) P2RX4GPR84PTPN1CES1LMNA
SCHEMBL11113522 0.80 P2RX4 (0.45) P2RX4GPR84CES1LMNATSHR
SCHEMBL14305634 0.78 P2RX4 (0.46) P2RX4CES1LMNATSHRMAPK1
SCHEMBL11622785 0.77 P2RX4 (0.45) P2RX4CES1LMNATSHRMAPK1
SCHEMBL13030142 0.77 P2RX4 (0.38) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL11108291 0.76 BCHE (0.54) P2RX4TSHRALDH1A1NPSR1BCHE
SCHEMBL11110072 0.76 P2RX4 (0.54) P2RX4CES1P2RX1P2RX3P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride AMOLI ORGANICS LTD. (IN) 2007-02-08 US claimed
EP-1678140-A2 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [B,F]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ [B,F] AZEPINE-5-CARBONYLCHLORIDE Amoli Organics Ltd. (IN) 2006-07-12 EP claimed
WO-2005066133-A2 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE AMOLI ORGANICS LTD. (IN) 2005-07-21 WO claimed
US-20210395231-A1 RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2021-12-23 US disclosed
EP-3760620-A1 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2021-01-06 EP disclosed
WO-2019161781-A1 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF 北京泰德制药股份有限公司 2019-08-29 WO disclosed
US-8530647-B2 Process for the preparation of oxcarbazepine MYLAN LABORATORIES LIMITED (IN) 2013-09-10 US disclosed
US-20110065917-A1 PROCESS FOR THE PREPARATION OF OXCARBAZEPINE MATRIX LABORATORIES LTD (IN) 2011-03-17 US disclosed
US-7858779-B2 Process for preparing oxcarbazepine ARCHIMICA S.R.L. (IT) 2010-12-28 US disclosed
US-7858779-B2 Process for preparing oxcarbazepine ARCHIMICA S.R.L. (IT) 2010-12-28 US disclosed
EP-1758867-B1 PROCESS FOR PREPARING OXCARBAZEPINE ARCHIMICA SRL (IT) 2010-09-29 EP disclosed
US-20070149507-A1 chlorocarbonylating, ammonolysis, and deprotecting; using triphosgene; without using corrosive reagents such as phosgene ARCHIMICA S.R.L. (IT) 2007-06-28 US disclosed
US-20070149507-A1 chlorocarbonylating, ammonolysis, and deprotecting; using triphosgene; without using corrosive reagents such as phosgene ARCHIMICA S.R.L. (IT) 2007-06-28 US disclosed
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride AMOLI ORGANICS LTD. (IN) 2007-02-08 US disclosed
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride AMOLI ORGANICS LTD. (IN) 2007-02-08 US disclosed
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride AMOLI ORGANICS LTD. (IN) 2007-02-08 US disclosed
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride AMOLI ORGANICS LTD. (IN) 2007-02-08 US disclosed
US-20060166968-A1 Crystalline form of oxcarbazepine DR. REDDY'S LABORATORIES, INC. 2006-07-27 US disclosed
EP-1678140-A2 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [B,F]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ [B,F] AZEPINE-5-CARBONYLCHLORIDE Amoli Organics Ltd. (IN) 2006-07-12 EP disclosed
WO-2005066133-A2 NOVEL PROCESS FOR PREPARATION OF 10-OXO-10, 11-DIHYDRO-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE (OXCARBAZEPINE) VIA INTERMEDIATE, 10-METHOXY-5H-DIBENZ[b,f] AZEPINE-5-CARBONYLCHLORIDE AMOLI ORGANICS LTD. (IN) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395231-A1 RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF TACR1, TACR2, GPBAR1 P2RX4 138/4885GPR84 25/4885PTPN1 450/4885
US-20070149507-A1 chlorocarbonylating, ammonolysis, and deprotecting; using triphosgene; without using corrosive reagents such as phosgene CA3, CTSG, PSEN2 P2RX4 2484/4885GPR84 3386/4885PTPN1 4230/4885
US-20060166968-A1 Crystalline form of oxcarbazepine CACNA1B, CACNA1C, CACNB4 P2RX4 3974/4885GPR84 2988/4885PTPN1 4597/4885
US-20110065917-A1 PROCESS FOR THE PREPARATION OF OXCARBAZEPINE CYP8B1, CYP4F12, CYP2F1 P2RX4 2052/4885GPR84 1343/4885PTPN1 4849/4885
US-20070032647-A1 Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride BRD9, KCNMB1, BTD P2RX4 3627/4885GPR84 1433/4885PTPN1 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.